UMIN試験ID | UMIN000028533 |
---|---|
受付番号 | R000032653 |
科学的試験名 | フレイル評価が治療関連合併症、予後に与える影響についての観察研究 |
一般公開日(本登録希望日) | 2017/08/06 |
最終更新日 | 2022/12/06 09:07:37 |
日本語
フレイル評価が治療関連合併症、予後に与える影響についての観察研究
英語
An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases
日本語
フレイル評価が治療関連合併症、予後に与える影響についての観察研究
英語
An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases
日本語
フレイル評価が治療関連合併症、予後に与える影響についての観察研究
英語
An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases
日本語
フレイル評価が治療関連合併症、予後に与える影響についての観察研究
英語
An observational validation study of the impact of Frailty on posttreatment adverse events and poor prognosis in patients with a patient with urological diseases
日本/Japan |
日本語
泌尿器科疾患
英語
Urological diseases
腎臓内科学/Nephrology | 内分泌外科学/Endocrine surgery |
泌尿器科学/Urology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
To evaluate the validity of Frailty for posttreatment adverse events and poor prognosis in patients with patient with urological diseases in multicenter setting
英語
To evaluate the validity of Frailty for posttreatment adverse events and poor prognosis in patients with patient with urological diseases in multicenter setting
有効性/Efficacy
日本語
英語
検証的/Confirmatory
実務的/Pragmatic
該当せず/Not applicable
日本語
Primary outcomes: Predicting frailty related post-treatment adverse events using Frailty Discriminant score
Secondary outcomes: Comparison of previously reported frailty assessment tools for diagnostic accuracy for frailty, Overall survival, Cancer-specific survival, Postoperative complication, Chemotherapy related to severe adverse events, Clinical indication for definitive therapies (surgery, chemotherapy and/or radiotherapy), Relationship between frailty and quality of life
英語
Primary outcomes: Predicting frailty related post-treatment adverse events using Frailty Discriminant score
Secondary outcomes: Comparison of previously reported frailty assessment tools for diagnostic accuracy for frailty, Overall survival, Cancer-specific survival, Postoperative complication, Chemotherapy related to severe adverse events, Clinical indication for definitive therapies (surgery, chemotherapy and/or radiotherapy), Relationship between frailty and quality of life
日本語
This study is a part of our prospective observational study (UMIN000025057). We planned the inter-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) when we successfully developed our CGA tool.
英語
This study is a part of our prospective observational study (UMIN000025057). We planned the inter-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) when we successfully developed our CGA tool.
観察/Observational
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
20 | 歳/years-old | 以上/<= |
100 | 歳/years-old | 以下/>= |
男女両方/Male and Female
日本語
Patients with urological diseases who undergo frailty assessments. Urological diseases include both malignant and non-malignant diseases.
英語
Patients with urological diseases who undergo frailty assessments. Urological diseases include both malignant and non-malignant diseases.
日本語
Patients with urological diseases who could not undergo frailty assessments.
英語
Patients with urological diseases who could not undergo frailty assessments.
600
日本語
名 | 真吾 |
ミドルネーム | |
姓 | 畠山 |
英語
名 | SHINGO |
ミドルネーム | |
姓 | Hataeyama |
日本語
Hirosaki University
英語
Hirosaki University
日本語
Urology
英語
Urology
036-8562
日本語
弘前市在府町5
英語
5 zaifu
0172395091
shingorilla2@gmail.com
日本語
名 | 真吾 |
ミドルネーム | |
姓 | 畠山 |
英語
名 | SHINGO |
ミドルネーム | |
姓 | Hatakeyama |
日本語
Hirosaki University Graduate School of Medicine
英語
Hirosaki University Graduate School of Medicine
日本語
Urology
英語
Urology
0368562
日本語
弘前市在府町5
英語
5 zaifu
0172395091
shingorilla2@gmail.com
日本語
弘前大学
英語
Hirosaki University Graduate School of Medicine
日本語
Hirosaki University Graduate School of Medicine
日本語
日本語
英語
日本語
弘前大学
英語
Hirosaki University Graduate School of Medicine
日本語
Hirosaki University Graduate School of Medicine
日本語
その他の国の官庁/Government offices of other countries
日本語
日本
英語
Japan
日本語
英語
日本語
英語
日本語
Hirosaki University Graduate School of Medicine
英語
Hirosaki University School of Medicine
日本語
5 Zaifu-chou
英語
5 Zaifu-chou
+81172395091
rinri@hirosaki-u.ac.jp
いいえ/NO
日本語
英語
日本語
英語
2017 | 年 | 08 | 月 | 06 | 日 |
https://pubmed.ncbi.nlm.nih.gov/31520152/
最終結果が公表されている/Published
https://pubmed.ncbi.nlm.nih.gov/31520152/
559
日本語
The FDS is a reliable and valid tool for assessing frailty and prognosis in patients with urological cancers.
英語
The FDS is a reliable and valid tool for assessing frailty and prognosis in patients with urological cancers.
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
英語
日本語
We prospectively validate the efficacy of the frailty discriminant score (FDS) in individuals with urological cancers, as there has been growing importance in evaluating frailty in clinical practice.
英語
We prospectively validate the efficacy of the frailty discriminant score (FDS) in individuals with urological cancers, as there has been growing importance in evaluating frailty in clinical practice.
日本語
A prospective, multicenter study was conducted from February 2017 to April 2019. We enrolled 258 patients with urological cancers and 301 community-dwelling participants who were assessed for frailty. Frailty was assessed using FDS that includes ten items, such as physical, mental, and blood biochemical tests.
英語
A prospective, multicenter study was conducted from February 2017 to April 2019. We enrolled 258 patients with urological cancers and 301 community-dwelling participants who were assessed for frailty. Frailty was assessed using FDS that includes ten items, such as physical, mental, and blood biochemical tests.
日本語
英語
日本語
The primary outcome was the non-inferiority (margin 5%) of FDS in discriminating patients with urological cancers from controls (Ctrl). The sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curve for each predictive test were calculated. The secondary endpoints included the prediction of overall survival between patients with urological cancer who have high and low FDS. FDS was significantly higher in patients with urological cancers than that in the Ctrl.
英語
The primary outcome was the non-inferiority (margin 5%) of FDS in discriminating patients with urological cancers from controls (Ctrl). The sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curve for each predictive test were calculated. The secondary endpoints included the prediction of overall survival between patients with urological cancer who have high and low FDS. FDS was significantly higher in patients with urological cancers than that in the Ctrl.
日本語
英語
日本語
英語
試験終了/Completed
2017 | 年 | 07 | 月 | 01 | 日 |
2016 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 07 | 月 | 02 | 日 |
2022 | 年 | 07 | 月 | 02 | 日 |
日本語
This study is an observational prospective validation study of the impact of Frailty Discriminant score on post-treatment adverse events and poor prognosis in patients with patient with urological diseases in multicenter setting. Patients in this study undergo frailty assessment including G8, gait speed, handgrip strength, fatigue and depression questionnaire, and basic blood biochemical test. Frailty Discriminant score were calculated, and outcomes are prospectively evaluated. Study interval is estimated for 5 years.
英語
This study is an observational prospective validation study of the impact of Frailty Discriminant score on post-treatment adverse events and poor prognosis in patients with patient with urological diseases in multicenter setting. Patients in this study undergo frailty assessment including G8, gait speed, handgrip strength, fatigue and depression questionnaire, and basic blood biochemical test. Frailty Discriminant score were calculated, and outcomes are prospectively evaluated. Study interval is estimated for 5 years.
2017 | 年 | 08 | 月 | 04 | 日 |
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000032653
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032653
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |